Blog
RSS FeedPosted by Michael Wonder on 28 Jun 2016
Cancer patients get another option with PHARMAC eyeing funding for Keytruda
28 June 2016 - Melanoma patients are likely to get a second drug treatment option under a new proposal to provide ...
Posted by Michael Wonder on 28 Jun 2016
Proposal relating to pembrolizumab (Keytruda), nivolumab (Opdivo), posaconazole (Noxafil) and raltegravir (Isentress)
28 June 2016 - PHARMAC recently announced a decision to fund nivolumab (Opdivo) for patients with unresectable or metastatic (stage III ...
Posted by Michael Wonder on 28 Jun 2016
Proposal to list cholic acid (Cholebiol) for rare disorder
28 June 2016 - PHARMAC is seeking feedback on a proposal to list cholic acid (Cholebiol) resulting from a provisional agreement ...
Posted by Michael Wonder on 27 Jun 2016
Proposal for sole subsidised supply of progestogen-only long-acting intra-uterine system (Mirena)
27 June 2016 - Following a request for proposals for the supply of a long-acting intra-uterine progestagen, PHARMAC is seeking feedback ...
Posted by Michael Wonder on 26 Jun 2016
Experimental immunotherapy drug reduces rare tumour size 'dramatically'
24 June 2016 - An experimental immunotherapy drug treatment has significantly reduced the size of a critically ill 36-year-old woman's rare ...
Posted by Michael Wonder on 24 Jun 2016
NICE publishes appraisal consultation for osimertinib mesylate (Tagrisso) for patients with non-small-cell lung cancer
24 June 2016 - NICE has published an appraisal consultation for AstraZeneca's Tagrisso. ...
Posted by Michael Wonder on 24 Jun 2016
PBS hospital medication charts
24 June 2016 - The PBS Hospital Medication Chart Project aims to improve the safety of medication management in Australian hospitals ...
Posted by Michael Wonder on 24 Jun 2016
Enoxaparin sodium and plerixafor proposal
24 June 2016 - PHARMAC is seeking feedback on a proposal involving enoxaparin sodium and plerixafor, resulting from a provisional agreement ...
Posted by Michael Wonder on 23 Jun 2016
Agenda for the 29 June 2016 TC meeting
23 June 2016 - The Transparency Commission will consider the reimbursement of migalastat hydrochloride (Galafold), lignocaine hydrochloride with phenylephrine hydrochloride and ...
Posted by Michael Wonder on 23 Jun 2016
UK trailing Europe on access to cancer drugs
23 June 2016 - The UK is trailing Europe on cancer spend, survival rates and patient access to new oncology medicines, ...
Posted by Michael Wonder on 23 Jun 2016
New guidance from NICE recommends Humira (adalimumab), the only licensed biologic for treatment of hidradenitis suppurativa, a debilitating and disfiguring skin condition
22 June 2016 - AbbVie today announced that the NICE has published single technology appraisal guidance for the only licensed ...
Posted by Michael Wonder on 23 Jun 2016
Agreement with Biotronik Australia for the supply of interventional cardiology devices
23 June 2016 - PHARMAC is pleased to announce the approval of an agreement with Biotronik Australia Pty Limited for the ...
Posted by Michael Wonder on 22 Jun 2016
CADTH calls for feedback on drugs for the management of rheumatoid arthritis
22 June 2016 - A list of included studies on drugs for the management of rheumatoid arthritis is now available for ...
Posted by Michael Wonder on 22 Jun 2016
NICE gives conditional backing for GSK’s Benlysta in lupus
22 June 2016 - NICE has today published final guidance which recommends UK pharma major GlaxoSmithKline’s Benlysta (belimumab) for treating systemic ...
Posted by Michael Wonder on 22 Jun 2016
UK drugs watchdog NICE approves five new treatments in coup for big pharma
22 June 2016 - The UK agency in charge of deciding which drugs the NHS will pay for has approved five ...